ESMO 2024 Prostate Cancer

Viewing 1-20 of 58 articles

ESMO 2024: Scientific Congress Highlights: Genitourinary Tumors, Prostate

ESMO 2024: Clinical Prognostic Factors Within the High-Volume Subgroup of Metastatic Hormone Sensitive Prostate Cancer in ENZAMET (ANZUP 1304)

ESMO 2024: HARMONY: A Phase II Study of Niraparib/Abiraterone Acetate plus Prednisone for Hispanic/Latinoand Non-Hispanic Black Patients with Metastatic Hormone Sensitive Prostate Cancer and Deleterious Homologous Recombination Repair Alterations

ESMO 2024: A New Prognostic Model of Overall Survival (OS) in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

ESMO 2024: First Preliminary Results of Artificial Intelligence Generated Treatment Recommendations for Urothelial Cancer Based on Multidisciplinary Cancer Conferences from the KITTU Project

ESMO 2024: Hematologic Impact of [177Lu]Lu-PSMA-617 Versus ARPI Change in Patients with Metastatic Castration-Resistant Prostate Cancer in PSMAfore

ESMO 2024: Targeting Epigenetic Pathways

ESMO 2024: Invited Discussant: CC-94676-PCA-001 and INSPIRE

ESMO 2024: Invited Discussant: RAPSON: Open-Label, Multicenter Randomized Trial of Radium-223 and Adding Metformin to ADT for Patients with mHSPC

ESMO 2024: Invited Discussant: Phase 3 ARANOTE Trial, Phase 3 Evaluation of Transdermal Estradiol vs LHRH Agonists and Ancillary Study of the PEACE-1

ESMO 2024: Efficacy and Safety of Darolutamide plus ADT in Patients with mHSPC from the Phase 3 ARANOTE Trial

ESMO 2024: Phenotypic and Genomic Characterization of De Novo Metastatic Prostate Cancer: An Ancillary Study of the PEACE-1 Phase 3 Trial

ESMO 2024: INSPIRE: Phase 2 Trial of Nivolumab 3mg/kg and Ipilimumab 1mg/kg in Molecularly Selected Patients with mCRPC

ESMO 2024: RAPSON: Open-Label, Multicenter Randomized Trial of Radium-223 -> Docetaxel Versus Docetaxel -> Radium-223 Sequence in mCRPC with Prospective Biomarker Evaluation

ESMO 2024: CC-94676-PCA-001: Clinical Activity of BMS-986365, a Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, in Heavily Pretreated Patients with mCRPC

ESMO 2024: Prostate Cancer Efficacy Results from a Randomized Phase 3 Evaluation of Transdermal Estradiol Versus LHRH Agonists for Androgen Suppression in M0 Prostate Cancer

ESMO 2024: Adding Metformin to ADT for Patients with mHSPC: Overall Survival Results from the Multi-Arm, Multi-Stage Randomized Platform Trial STAMPEDE

ESMO 2024: Invited Discussant: CONTACT-02 Study and STAMPEDE Docetaxel Trials

ESMO 2024: Cabozantinib plus Atezolizumab versus 2nd Novel Hormonal Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Results of the Phase III, Randomized, CONTACT-02 Study

ESMO 2024: Decipher® mRNA Score for Prediction of Survival Benefit from Docetaxel at Start of Androgen Deprivation Therapy for Advanced Prostate Cancer: An Ancillary Study of the STAMPEDE Docetaxel Trials

1
2
3